Mitoxantrone slowed progression of disability and reduced relapses in multiple sclerosisMitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.

  • Murray, T Jock MD (commentator)
  • Hartung, HP
  • Gonsette, R
  • Konig, N
  • et al,

  • Dalhousie University Halifax, Nova Scotia, Canada

Hartung HP, Gonsette R, König N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018–25HartungHPGonsetteRKonigNet alMitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial.Lancet20023602018-25

Source of funding: Wyeth-Lederle.

For correspondence: Professor HP Hartung, Heinrich-Heine-Universität, Düsseldorf, Germany. [email protected]

*

See glossary.

Evidence Based Medicine 8(5):p 148, September-October 2003.
Copyright © British Medical Journal 2003.